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Objective: Surgical arterial thromboembolectomy (TE) is an efﬁcient treatment for acute arterial thromboemboli of lower
limbs, especially if a single large artery is involved. Unfortunately, residual thrombus, propagation of thrombi, chronic
atherosclerotic disease, and vessel injuries secondary to balloon catheter passage may limit the clinical success rate.
Intraoperative angiography can identify any arterial imperfection after TE, which may be corrected simultaneously by
endovascular techniques (so-called “hybrid procedures,” HP). The aim of this study is to compare outcomes of surgical
TE vs HP in patients with acute lower limb ischemia (ALLI).
Methods: From 2006 to 2012, 322 patients with ALLI were admitted to our department. Patients received urgent surgical
treatment using only a Fogarty balloon catheter (TE group[ 112) or in conjunction with endovascular completion (HP
group [ 210). In-hospital complications, 30-day mortality, primary and secondary patency, reintervention rate, limb
salvage, and overall survival rates were calculated using the Kaplan-Meier method and compared by log-rank test.
Results: HPs (n [ 210) following surgical TE consisted of angioplasty (PTA) 6 stenting in 90 cases, catheter-directed
intra-arterial thrombolysis D PTA 6 stenting in 24, thrombus fragmentation and aspiration by large guiding
catheter D PTA 6 stenting in 67, vacuum-based accelerated thromboaspiration by mechanical devices in 9, and
primary covered stenting in 12. Estimated primary patency was 90.4% vs 70.4% at 2-year and 87.1% vs 66.3% at 5-year
follow-up, respectively, for HP and TE patients (hazard ratio, 3.1; 95% conﬁdence interval, 1.78-5.41; P < .01). A
hazard ratio of 2.1 for limb salvage was noted for the HP group (95% conﬁdence interval, 1.01-4.34; P [ .03).
Estimated freedom from reintervention at 1 year was 94.4% for HP vs 82.1% for TE patients, and 89% vs 73.7% at
5 years, respectively (P [ .04).
Conclusions: HPs for ALLI may represent the tools that, when applied to speciﬁc clinical scenarios, hold the potential to
reduce the morbidity previously associated with acute arterial occlusion. (J Vasc Surg 2014;59:729-36.)Surgical arterial thromboembolectomy (TE) using
a Fogarty balloon catheter is an efﬁcient treatment for
acute arterial emboli of lower limbs, especially when a single
large vessel is involved.1 Despite this, the early clinical
outcome still remains unsatisfactory in a number of cases.2
It has been well established that intraoperative angiography
after TE may frequently detect arterial imperfections, such
as incomplete restoration of perfusion in below-the-knee
(BTK) arteries, propagation of thrombi, or presence of
underlying steno-occlusive lesions,3,4 which may be res-
ponsible for the early failure. Finally, even vessel injuries
secondary to balloon catheter passage may limit the clinical
success rate.the Department of Medicine, Surgery, and Neuroscience, Vascular
d Endovascular Surgery Unit, University of Siena.
or conﬂict of interest: none.
ented at the 2013 Vascular Annual Meeting of the Society for Vascular
rgery, San Francisco, Calif, May 30-June 1, 2013.
rint requests: Gianmarco de Donato, MD, Department of Medicine,
rgery and Neuroscience, Vascular and Endovascular Surgery Unit,
niversity of Siena, Viale Bracci, 53100 Siena, Italy (e-mail: dedonato@
isi.it).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2013.09.016An alterative to surgery, percutaneous catheter-directed
thrombolysis (CDT), has been proposed. A systematic
review of data from the randomized trials performed in
the mid-1990s concluded that operative revascularization
or CDT in patients with acute lower limb ischemia (ALLI)
carries similar major amputation and mortality rates,
although CDT was associated with higher rates of hemor-
rhage and stroke at 30 days and an increased risk of distal
embolization.5
Over the last decade, various additional percutaneous
techniques have been proposed for the treatment of
ALLI, including mechanical thrombolysis, thrombus frag-
mentation and intraluminal thromboaspiration, angio-
plasty, and covered stenting.
The role of the combination of surgical embolectomy
and endovascular techniques (so-called “hybrid proce-
dures,” or HP) for treatment of patients presenting with
ALLI has not been established yet. The aim of this study
is to compare outcomes of surgical TE vs HP in patients
with ALLI.
METHODS
Patient selection. From January 2006 to September
2012, all patients who presented at our department with
acute rising of the symptomatology suggestive for ALLI
(less than 14 days) were included in a dedicated database.
Patients with acute ischemia due to graft occlusion were729
Fig 1. Flowchart of group allocation. ALLI, Acute lower leg
ischemia; HP, hybrid procedure; TE, thromboembolectomy.
Table I. Baseline characteristics of patients
Characteristic
Group TE
(n ¼ 112)
Group HP
(n ¼ 210)
P
value
Mean age 6 SD, years 72.5 6 10.3 73.3 6 11.6 .4
Gender, male/female 71/41 121/89 .3
Current/former smokers, % 49.1 53.8 .49
Medical history/concomitant
conditions, %
Ischemic cardiopathy 25.0 27.5 .5
Cerebrovascular disease 13.4 14.7 .5
Atrial ﬁbrillation/
arrhythmias
53.6 39.1 .01
Chronic peripheral arterial
disease
17.8 26.2 .09
Previous revascularization
lower limb(s)
16.9 20.4 .3
Hypertension 61.6 59.0 .3
Diabetes 21.4 20.4 .3
Duration of symptoms, %
0-6 hours 16.9 12.4 .1
6-24 hours 29.5 31.4 .4
>24 hours 53.6 56.2 .4
Clinical category of acute
ischemia, %
Class I 2.7 2 .6
Class IIa 44.6 48.1 .5
Class IIb 39.3 35.2 .3
Class III 13.4 14.7 .8
HP, Hybrid procedure; SD, standard deviation; TE, thromboembolectomy.
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well as operative details, were prospectively collected, and
retrospectively analyzed.
On a total of 322 patients with ALLI, interrogation of
the database on the type of treatment (surgery vs surgery þ
endovascular HP) identiﬁed two groups of patients (Fig 1):
(1) group 1: patients who received urgent surgical treat-
ment only by Fogarty catheter TE (TE group; n ¼ 112)
and (2) group 2: patients who received HP (HP group,
n ¼ 210). Table I shows baseline characteristics of patients.
Surgical strategy. When a diagnosis of ALLI is
conﬁrmed by clinical examination and duplex ultrasound
performed by the on-call vascular surgeon, our protocol
includes the immediate infusion of continuous intravenousheparin sodium (z20,000-40,000 units/24 hours in
50 mL of saline injection) to limit the propagation of
thrombus and prevent clinical deterioration. The dosage of
heparin is adjusted according to the patient’s coagulation
test results, considering adequate an activated partial
thromboplastin time of 2 to 2.5 times the control value.
Surgical intervention is immediately planned and per-
formed as soon as possible according to the availability of
an operating theater.
Most of our patients are approached through
a common or superﬁcial femoral artery (SFA) exposure,
which permits access for a balloon catheter TE from the
aortic bifurcation to the ankle. Occasionally, below-knee
trifurcation arterial exposure with tibial-peroneal arterial
TE may be required.
A bolus of 5000 UI of heparin sodium is administered
intravenously, just before arteriotomy and TE by Fogarty
balloon catheter of a diameter well matched to the target
artery (range, 2-5 F).
After TE, all patients receive intraoperative assessment
of the adequacy of clot removal by physical examination
(presence of femoral, popliteal, and tibial pulses), by
continuous wave (CW) Doppler evaluating the ﬂow of
the peroneal, posterior, and anterior tibial arteries at ankle
level, and, selectively, by completion angiography. The
decision to perform an on-table angiography is based on
several factors, mainly the following four: (1) the absence
of satisfactory back-bleeding from distal vessels; (2) the
demonstration of signals of poor revascularization by the
CW Doppler at the ankle; (3) the poor clinical appearance
Table II. Location of surgical cutdown
Cutdown
TE group (n ¼ 112),
No. (%)
HP group (n ¼ 210),
No. (%)
CFA 51 (45.5) 86 (40.9)
SFA 30 (26.8) 53 (25.2)
BK popliteal 14 (12.5) 33 (15.7)
CFA þ BK popliteal 11 (9.8) 22 (10.4)
SFA þ BK popliteal 6 (5.3) 16 (7.6)
BK popliteal, Below-the-knee popliteal artery; CFA, common femoral
artery; HP, hybrid procedure; SFA, superﬁcial femoral artery; TE,
thromboembolectomy.
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catheter far enough distally.
Angiography is generally performed by direct puncture
of the exposed artery, or, in case of BTK arterial exposure,
by puncture of the ipsilateral common femoral artery.
When the angiography diagnoses an incomplete resto-
ration of perfusion, then different endovascular options are
evaluated based on the location and length of residual clot.
A catheter-directed intra-arterial thrombolytic therapy
using a multisided port catheter passed through the
residual thrombus is preferred when the amount of residual
thrombus is longer than 15 cm. In such cases, after deliv-
ering a single ranging 3- to 5-mg dose of recombinant
tissue-type plasminogen activator (Alteplase) throughout
the occlusion, a continuous infusion for 24 hours is
continued at 0.5 to 1.0 mg/kg/h (20 mg maximum).
The thrombolytic catheter is generally placed through the
open incision, although we prefer ﬁrst to suture the arterio-
tomy used for the TE, and then we puncture the exposed
artery at a different point and insert the thrombolytic cath-
eter. A concomitant low-dose of heparin (300 to 500 units
per hour) is typically infused through the arterial access
sheath to prevent thrombosis around the sheath. A comple-
tion angiography is performed after 24 hours.
Distinctive percutaneous options are evaluated in cases
of residual thrombosis <15 cm in length. These include
mechanical thrombectomy techniques, which are ﬁnalized
to clear the remaining intravascular thrombus by thrombus
fragmentation and aspiration, and vacuum-based acceler-
ated thromboaspiration and lysis.
When the completion angiography reveals the presence
of an underlying atherosclerotic steno-occlusive lesion after
clot removal, a plain balloon angioplasty (PTA) is per-
formed, and a nitinol stent is implanted in case of residual
stenosis >30% or ﬂow-limiting dissections (bailout stent-
ing). Primary covered stenting is also considered in cases
of persistent partial intraluminal thrombosis adherent to
the arterial wall after TE.
Standard anticoagulation with intravenous heparin is
generally applied in the early postoperative period. In all
patients with atrial ﬁbrillation or in the presence of other
cardiac sources of emboli, prosthetic cardiac valves, or
a known hypercoagulable state, warfarin anticoagulation
is initiated some days after intervention with a long-term
target international normalized ratio of 2 to 3.
Remaining patients, or those with contraindications to
warfarin anticoagulation, receive an antiplatelet agent (clo-
pidogrel 75 mg/day or aspirin 100 mg/day or ticlopidine
250 mg twice a day) henceforth. A 1-month dual antipla-
telet therapy (clopidogrel 75 mg/day þ aspirin 100 mg/
day) is also suggested in cases of stent deployment.
Follow-up protocol. An ultrasound examination is
performed within 48 hours of revascularization and
repeated at day 30, at 3, 6, 9, and 12 months, and then
yearly. The clinical status of the patients and duplex-
ultrasound is evaluated at the same intervals. The ultra-
sound examination measures the patency of the treated
arteries and any evidence of internal thrombus. Allexaminations are performed in the same vascular labora-
tory, using the same ultrasound machines (Ultramark IU-
22 and HDI 3500 ATL-Philips, Eindhoven, Holland).
The B-mode imaging frequency is 7 MHz, and the pulsed-
wave Doppler frequency is 4 MHz.
The criteria for reintervention during follow-up are
based on clinical symptoms (clinically driven revasculariza-
tion). Repeat percutaneous or surgical interventions are
planned only in case of the presence of rest pain, ischemic
lesions (primary ulcer or nonhealing ulcer), or disabling
intermittent claudication, while asymptomatic partial or
complete reocclusions of the previously treated arterial
segment are managed conservatively.
Deﬁnitions and end points. Clinical outcomes,
primary patency, secondary patency, and complications
following revascularization were reported according to
the “Recommended standards for reports” by Rutherford
et al.6 Primary technical success of HP was deﬁned as
continuous arterial patency of at least one artery to the foot
without any obvious ﬂow-limiting lesions (absence of
a stenosis >50%). Patency of the peroneal artery with good
collateral ﬂow to the dorsalis pedis artery or to the plantar
arteries was also considered a primary technical success.
Limb salvage was deﬁned as no amputation proximal to
the metatarsus.
In-hospital complications, 30-day mortality, primary
and secondary patency, freedom from reintervention,
freedom from amputation, and overall survival rates were
calculated for the two study groups.
Statistical analysis. The data were expressed as mean
and standard deviation or as median and interquartile
range, depending on the type of distribution. All results
were analyzed using MedCalc version 12.5.0.0 (MedCalc
Software bvba, Ostend, Belgium). Comparison of baseline
characteristics between treatment groups was calculated by
t-test or c2 test, as appropriate.
Kaplan-Meier curves were used to calculate the
survival, primary and secondary patency, freedom from
reintervention, and limb salvage rates. Log-rank test was
used for the comparison between the survival curves of
the two study groups. If the P value associated with the
c2 statistic was small (<.05), then the conclusion was
that, statistically, the two survival curves differ signiﬁcantly,
or that the grouping variable (ie, type of intervention: TE
vs HP) had a signiﬁcant inﬂuence on survival time.7
Fig 2. Findings at intraoperative angiography after thromboembolectomy (TE) in the hybrid procedure (HP) group.
BTK, Below-the-knee; SFA, superﬁcial femoral artery.
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(CI) was also calculated.
RESULTS
All patients underwent surgical revascularization by TE
as ﬁrst-line treatment. Location of surgical cutdown is
summarized in Table II. In some patients, a combined
exposure of the common femoral artery and distal popliteal
artery was necessary.
On the basis of intraoperative ﬁndings, an on-table angi-
ography was performed in 242 out of 322 patients (Fig 1).
The angiography conﬁrmed the need of further endovascu-
lar treatment in 210 cases (HP group). Indications to
proceed with endovascular revascularization were the pres-
ence of: (1) chronic atherosclerotic disease at SFA or BTK
vessels considered responsible for the acute thrombosis
(so-called “stenosis underlying the thrombosis”) in 90 cases;
(2) incomplete recanalization due to residual thrombus in
SFA and popliteal ﬁrmly adherent to the arterial wall in 54
cases; (3) residual thrombus in BTK vessels, which have
not been appropriately reached by the balloon catheter
TE, in 58 cases; (4) iatrogenic lesions of the arterial wall
secondary to the intraluminal passage of the Fogarty balloon
catheter in eight cases (intimal ﬂap, n ¼ 5; perforation,
n ¼ 1; post-traumatic aneurysm, n ¼ 1; Fig 2).
For the purpose of this analysis, the TE group (n ¼
112) included patients treated only by Fogarty balloon
TE (n ¼ 80) and patients with no need of further treat-
ment at intraoperative angiography (n ¼ 32; Fig 1).
The two groups of analysis were similar in terms of
gender, median age, and risk factors, except for the inci-
dence of atrial ﬁbrillation or arrhythmia, that was statisti-
cally higher in the TE group (53.6% vs 39.1%; P ¼ .01).
A nonsigniﬁcant statistical trend was also noted for the
rate of previous peripheral arterial disease (deﬁned ashistory of intermittent claudication, rest pain, or ulcer) in
HP patients (17.8% vs 26.2; P ¼ .09; Table I).
Different endovascular options were offered to pa-
tients with positive ﬁndings at intraoperative angiography.
In the presence of chronic atherosclerotic disease of native
arteries underlying the thrombosis (n ¼ 90), a PTA was
performed, followed by nitinol stent implantation in 31
cases (Table III).
A catheter-directed intra-arterial thrombolytic the-
rapy was performed in 24 cases, due to the evidence of
a large amount of residual thrombosis (>15 cm in length)
at intraoperative angiography. The angiography after
24 hours showed the presence of lesions requiring further
endovascular treatment in 14 cases (PTA, n ¼ 11; stent-
ing, n ¼ 3).
Alternative endovascular solutions in cases of residual
thrombosis <15 cm in length were thrombus fragmenta-
tion and aspiration by a large guiding catheter in 67 cases
and vacuum-based accelerated thromboaspiration by
mechanical devices (AngioJet Ultra Thrombectomy
System; Medrad, Inc, Warrendale, Pa; standard and
power-pulse spray technique) in nine cases. Thrombo-
aspiration was followed by PTA 6 stenting in the majority
of cases (Table III).
Primary covered stenting was also considered in cases
of incomplete luminal thrombosis (n ¼ 12).
Vessel injuries after TE were ﬁxed by prolonged PTA
(n ¼ 5) and additional stenting (n ¼ 3).
Primary technical success of HP was 99.1%.
No intraoperative deaths occurred. The mortality rate
at 30 days was 3.7% (12 of 322), due to myocardial infarc-
tion (n ¼ 4), acute renal failure (n ¼ 2), congestive heart
failure (n ¼ 4), or multiorgan failure syndrome (n ¼ 2).
In-hospital complications occurred in 17 patients in group
TE and 29 patients in group HP (P ¼ .07). The incidence
Table III. Details of surgical and endovascular procedures in the hybrid procedure (HP) group
Open
surgery
Findings at intraoperative
angiography Endovascular solution adopted Level Adjuvant procedure
TE Native arterial lesions (stenosis
underlying the thrombosis)
n ¼ 90
PTA (n ¼ 59);
PTA þ stenting (n ¼ 31)
SFA (n ¼ 54);
Popliteal (n ¼ 2);
BTK (n ¼ 21);
SFA and BTK (n ¼ 13)
None
TE Residual thrombus (>15 cm
in length)
n ¼ 24
Catheter-directed intra-
arterial thrombolysis
(n ¼ 24)
SFA (n ¼ 2);
BTK (n ¼ 9);
SFA popliteal and BTK (n ¼ 8);
Popliteal and BTK (n ¼ 5)
Thromboaspiration
(n ¼ 5);
PTA (n ¼ 11);
PTA þ stenting (n ¼ 3)
TE Residual thrombus (<15 cm
in length)
n ¼ 76
Thrombus fragmentation and
aspiration by large guiding
catheter (n ¼ 67)
SFA (n ¼ 11);
Popliteal (n ¼ 7);
BTK (n ¼ 21);
SFA popliteal and BTK (n ¼ 13);
Popliteal and BTK (n ¼ 15)
PTA (n ¼ 41);
PTA þ stenting (n ¼ 5)
Vacuum-based accelerated
thromboaspiration by
mechanical devices
(n ¼ 9)
SFA (n ¼ 1);
BTK (n ¼ 6);
Popliteal and BTK (n ¼ 2)
PTA (n ¼ 3);
PTA þ stenting (n ¼ 1);
pulse spray thrombolysis
(n ¼ 5)
TE Incomplete luminal
thrombosis
n ¼ 12
Primary covered stenting
(n ¼ 12)
SFA (n ¼ 11);
Popliteal (n ¼ 1)
None
TE Vessel injury after Fogarty
catheter passage
n ¼ 8
Prolonged PTA (n ¼ 5)
þ additional stenting
(n ¼ 3)
SFA (n ¼ 2);
Popliteal (n ¼ 1);
BTK (n ¼ 5)
None
BTK, Below-the-knee vessels; PTA, percutaneous transluminal angioplasty; SFA, superﬁcial femoral artery; TE, thromboembolectomy.
Table IV. Early complications
TE group
(n ¼ 112),
No. (%)
HP group
(n ¼ 210),
No. (%) P
30-day mortality 5 (4.4) 7 (3.3) .5
In-hospital complications 17 (15.1) 29 (13.8) .7
Cardiac (myocardial infarction,
congestive heart failure)
7 8 .4
Neurological (stroke) 2 3 1
Renal 3 3 1
Pulmonary 2 5 1
Hematoma at level of surgical
cutdown
3 10 .5
HP, Hybrid procedure; TE, thromboembolectomy.
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(P ¼ .04), while hematoma at level of surgical cutdown
was more frequent in the HP group (P ¼ .05; Table IV).
The mean length of follow-up was 989 6 52 days
(range, 30-2175 days), and 27 patients were lost to
follow-up during the study period. Figs 3-6 show the
Kaplan-Meier curves of survival, primary and secondary
patency, and limb salvage rates for the two study groups.
Cumulative survival rate at 5 years was 82.8% (no statistical
difference between the two study groups). The primary
patency was 92.4% vs 77.5% at 1-year, 90.4% vs 70.4% at
2-year, and 87.1% vs 66.3% at 5-year follow-up, respec-
tively, for HP and TE patients (HR, 3.1; 95% CI, 1.78-
5.41; P < .01; Fig 4). Secondary patency at 2 years in
HP patients was 97.8% in HP patients vs 90.1% in TE
patients (HR, 3.9; 95% CI, 1.41-10.90; P < .01; Fig 5).
An HR of 2.1 for limb salvage was noted for the HP
group (95% CI, 1.01-4.34; P ¼ .03; Fig 6).
Estimated freedom from reintervention at 1 year was
94.4% for HP vs 82.1% for TE patients and 89% vs
73.7% at 5 years, respectively (P ¼ .04; Fig 7). The reinter-
ventions performed were either redo surgery (TE by
Fogarty’s catheter, n ¼ 8; bypass surgery, n ¼ 11), endo-
vascular (PTA 6 stenting, n ¼ 6; CDT, n ¼ 8), or hybrid
intervention (n ¼ 12).DISCUSSION
While improvements in surgical techniques and perio-
perative patient care have occurred over the years, theresults available document a persistently high medical
need for patients presenting with ALLI, with a reported
30-day amputation rate of 5% to 12%, mortality risk of
10% to 38%, and combined incidence of amputation and
death of 25% to 37.5% at 6-month follow-up.8-11 In clinical
practice, there is a discrepancy between the immediate
technical success of arterial TE that often seems adequate,
and the early clinical outcome that still remains unsatisfac-
tory in a number of cases. This incongruence may be
related to the incomplete restoration of perfusion due to
residual thrombus in distal vessels inaccessible to the
balloon embolectomy or to the propagation of residual
thrombi. Both historical experimental and clinical studies
have shown that clot removal is frequently incomplete
Fig 3. Survival curves. CI, Conﬁdence interval; DF, degrees of
freedom; HP, hybrid procedure; TE, thromboembolectomy.
Fig 4. Primary patency curves.CI,Conﬁdence interval;DF, degrees
of freedom; HP, hybrid procedure; TE, thromboembolectomy.
Fig 5. Secondary patency curves. CI, Conﬁdence interval;
DF, degrees of freedom; HP, hybrid procedure; TE, throm-
boembolectomy.
Fig 6. Limb salvage curves. CI, Conﬁdence interval; DF, degrees
of freedom; HP, hybrid procedure; TE, thromboembolectomy.
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graphically and by ﬁber optic angioscopy in small distal
vessels in 36% to 82% of patients.3,4 Our study conﬁrms
that, when an adequate intraoperative angiogram after TE
is performed, the detection of imperfect revascularizationneeding treatment is very high (86%; 210 HPs out of
242 on-table angiographies).
The ﬁrst attempt to improve the surgical technique
for treating acute arterial occlusion was described by
Fig 7. Freedom from reintervention curves. CI, Conﬁdence
interval; DF, degrees of freedom; HP, hybrid procedure; TE,
thromboembolectomy.
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tive ﬂuoroscopy and the performance of ﬂuoroscopically
assisted TE, the authors described the ﬁrst example of
combination of surgical and endovascular technique for
treatment of ALLI. This original HP turned out to
improve the technical success of TE. Facilitating the cath-
eter passage through tortuous or diseased arteries, this
new technique minimized arterial damage and blood loss
during clot removal. It had also the potential to facilitate
accurate identiﬁcation, localization, and treatment of
signiﬁcant concomitant arterial lesions.
Since then, it has been recommended to perform
a routine angiography after TE,13,14 but adherence to
this recommendation is still limited in clinical practice.15
Our experience conﬁrms the central role of intraopera-
tive angiography after TE in deﬁning the need for as well as
guiding adjunctive endovascular procedures, which are the
keys for better early and midterm outcomes of ALLI
patients. If a surgical strategy with on-table angiography
in all cases is not possible, at least it should be advocated
every time a BTK intervention is done.
CDT has been used as an alternative to surgical embo-
lectomy for ALLI with gratifying results, but its success is
related to the ability to pass a guide through and embed
a multisided catheter into the occlusion.16,17 Results from
randomized trials comparing the two treatments reveal
that thrombolysis has the greatest advantage in acute pros-
thetic bypass graft occlusions, while patients with ALLI due
to native arterial occlusions tend to be associated with infe-
rior results after thrombolysis, consisting in higher rates ofhemorrhage and stroke at 30 days, and increased risks of
distal embolization.5,18
These data have inﬂuenced our clinical protocol in the
management of ALLI patients. In our center, a ﬁrst-line
treatment by CDT is reserved for ALLI due to bypass graft
thrombosis, while operative revascularization is generally
the preferred initial option for patients with native arterial
occlusions. Our experience showed that completion angi-
ography after TE can not only identify residual thrombus
in distal vessels but also incomplete recanalization of
more proximal arteries due to residual thrombus strongly
adherent to the arterial wall, or can reveal the presence of
signiﬁcant underlying steno-occlusive lesions after clot
removal. In a limited number of cases (3.3%), angiography
can even demonstrate the existence of vessel injuries
secondary to incorrect balloon catheter passage. These
points clearly call for a routine and accurate intraoperative
assessment of the adequacy of clot removal, which may be
performed by angiography, angioscopy, or intravascular
ultrasound.
It has been a common belief in the past to rely on the
presence or absence of back-bleeding from a peripheral
arterial bed as a guide to distal arterial patency. Actually,
we know that visual evaluation of outﬂow may be ambig-
uous to truly prove that adequate circulation has been
restored, since irregular thrombotic material may be
present in approximately one-third of cases,11 and back-
bleeding may be quite misleading in cases of adequate
collateral circulation, despite the occurrence of total distal
obstruction.
Percutaneous mechanical thrombectomy devices have
been proposed over the past decade to speed up the time
required for dissolution of thrombus by pharmacologic
means and to reduce the amount of thrombolytic agent
used.19 These devices have been developed for aspiration
and dissolution of small amounts of thrombotic material
during coronary procedures, while the clot quantity in cases
of ALLI may be much larger, resulting in 25% to 30% inad-
equate clot removal in patients presented with occlusion of
native vessels or grafts.20,21 Moreover, large particulate
debris and microembolization has been described with all-
mechanical thrombectomy, as well as the inability to
completely remove huge and well-organized thrombi
when densely adherent to the arterial wall.22,23
Additionally, the rapid stream of ﬂuid and hydrody-
namic forces used by thrombectomy devices may cause
a signiﬁcant amount of red blood cell hemolysis resulting
in hemoglobinemia and hemoglobinuria. This may occur
when repeated passes of the device are required, resulting
in severe consequences, mainly in patients with renal
insufﬁciency.24
Consequently, we believe that surgical TE is still the
most effective and less time-consuming solution in
removing a large clot from the femoropopliteal arterial
segment.
Percutaneous pharmacological or mechanical throm-
bolysis, applied as an adjuvant procedure to surgery, may
improve results by clearing a reasonable amount of clot
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success (99.1%).
Patients treated by HP had better primary and
secondary patency rates as well as lower reintervention
rates, which were already evident at 1-year, and were
conﬁrmed at 3- and 5-year analysis. As a result, HP patients
had an individual clinical beneﬁt consisting in improved
limb salvage rate from the 3rd year onward (Fig 6).
Limitations. A limitation of the present study is that
completion angiography was performed selectively, based
on subjective and independent parameters. This may have
introduced bias in favor of HP.
CONCLUSIONS
Some kind of intraoperative imaging study is advisable
because of a high incidence of underlying lesions that can
cause acute arterial occlusion. The combination of surgical
and endovascular options, appropriately selected on the
angiographic ﬁndings after TE, may overcome the limita-
tions that characterize the traditional approach in patients
with ALLI. HPs may represent the tools that, when applied
to speciﬁc clinical scenarios, hold the potential to reduce
the morbidity previously associated with acute arterial
occlusion and improve early and midterm clinical
outcomes.
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